#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    General anaesthesia Hypergammaglobulinaemia benign monoclonal Pemphigoid Osteosarcoma metastatic Acute graft versus host disease Ovarian cancer Castleman's disease Cryoglobulinaemia Kearns-Sayre syndrome Kaposi's sarcoma Splenic marginal zone lymphoma Extra-osseous Ewing's sarcoma recurrent Lymphoma Biliary cancer metastatic Small cell lung cancer limited stage More trials…

    Learn about Rare Diseases

    Waldenstrom’s macroglobulinaemia recurrent – Basic Information Brain stem glioma – Diagnostics Leiomyosarcoma – Trials in Disease Toxic epidermal necrolysis – Basic Information X-linked lymphoproliferative syndrome – Life with Disease Retinitis pigmentosa – Treatment Paroxysmal nocturnal haemoglobinuria – Trials in Disease Biotinidase deficiency – Basic Information Wiskott-Aldrich syndrome – Treatment Tuberous sclerosis complex – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Danazol Triptorelin Acetate IM-101 Peboctocogene Camaparvovec Seladelpar Dexmedetomidine Posdinemab ARLOCABTAGENE AUTOLEUCEL RNMB2 Pamiparib Dabigatran Etexilate Sacubitril Zetomipzomib Ly3541860 Tiratricol GRNA1599 Gfh925 Amitriptyline Hydrochloride Golodirsen Placebo More therapies…

    Learn about Your Condition

    Gender dysphoria Primary myelofibrosis Normal pressure hydrocephalus Anorexia nervosa Deafness bilateral Metachromatic leukodystrophy Wolfram syndrome Pseudomyxoma peritonei Cholangitis sclerosing Adenosquamous cell lung cancer Liver transplant B-cell lymphoma refractory Paget's disease of the vulva Plasmablastic lymphoma Cluster headache More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut Jules Bordet

Institut Jules Bordet

Mijlenmeersstraat 90, Anderlecht, 1070, Belgium

Want to learn more about this study or check if you can participate? Contact us.

  • A Study of BMS-986504 Combined with Nab-Paclitaxel and Gemcitabine for Patients with Untreated Metastatic Pancreatic Cancer with MTAP Gene Deletion

    Recruiting

    4 1 1
    Investigated Drugs:
    • 2-[4-[4-(AMINOMETHYL)-1-OXO-2H-PHTHALAZIN-6-YL]-2-METHYLPYRAZOL-3-YL]-4-CHLORO-6-CYCLOPROPYLOXY-3-FLUOROBENZONITRILE
    • Gemcitabine
    • Paclitaxel Albumin-Bound
    Austria Belgium Czechia Denmark France Germany +9

  • A Study of Puxitatug Samrotecan Compared to Chemotherapy for Patients with Advanced Endometrial Cancer After Previous Platinum and Immunotherapy Treatment

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Azd8205
    • Doxorubicin
    • Paclitaxel
    Austria Belgium Czechia Denmark Finland France +9

  • A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Capivasertib
    • RLY-2608
    • Fulvestrant
    Austria Belgium Bulgaria Czechia Denmark France +10

  • Study of Different Dosing Schedules of Osimertinib in Patients with EGFR Mutated Advanced or Metastatic Non-Small Cell Lung Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer metastatic
    Investigated Drugs:
    • Osimertinib
    Belgium The Netherlands

  • A study comparing BNT323 with chemotherapy in patients with HER2-expressing recurrent endometrial cancer who received previous treatment

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Endometrial cancer recurrent
    • Endometrial cancer
    Investigated Drugs:
    • Db-1303
    • Docetaxel
    • Doxorubicin Hydrochloride
    Austria Belgium Czechia Denmark Finland France +9

  • Study of BNT326 alone and with BNT327 in patients with advanced solid tumors: Testing safety and effectiveness of new cancer treatments

    Recruiting

    1 1 1
    Investigated Drugs:
    • BNT327
    Belgium Germany Italy Spain

  • Study of PF-07248144 and fulvestrant in adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who had progression after CDK4/6 inhibitor therapy

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • 2-METHOXY-N-{4-METHOXY-6-[(1H-PYRAZOL-1-YL)METHYL]-1,2-BENZOXAZOL-3-YL}BENZENE-1-SULFONAMIDE
    • Everolimus
    • Exemestane
    Belgium Bulgaria Czechia Finland France Germany +8

  • Study of testosterone supplementation to improve quality of life in male patients receiving palliative care who have androgen deficiency

    Recruiting

    2 1 1 1
    Belgium

  • Study of 177Lu-FAP-2286 alone and with drug combinations for patients with advanced solid tumors including non-small cell lung cancer, breast cancer, and pancreatic cancer

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • 177LU-FAP-2286
    • Calcium Folinate
    • Fluorouracil
    Belgium France Italy Spain

  • Study of personalized treatment using drug combination therapy for young women with early stage hormone receptor-positive breast cancer based on gene expression testing

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Epirubicin
    • Goserelin
    • Triptorelin
    Belgium France Greece Ireland Italy Poland +1
Previous Page
1 2 3 4 5 … 22
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!